MX9702336A - Composiciones de vacuna. - Google Patents

Composiciones de vacuna.

Info

Publication number
MX9702336A
MX9702336A MX9702336A MX9702336A MX9702336A MX 9702336 A MX9702336 A MX 9702336A MX 9702336 A MX9702336 A MX 9702336A MX 9702336 A MX9702336 A MX 9702336A MX 9702336 A MX9702336 A MX 9702336A
Authority
MX
Mexico
Prior art keywords
immune response
chitosan
antigens
influenza virus
vaccine compositions
Prior art date
Application number
MX9702336A
Other languages
English (en)
Other versions
MXPA97002336A (es
Inventor
Steven Neville Chatfield
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Publication of MXPA97002336A publication Critical patent/MXPA97002336A/es
Publication of MX9702336A publication Critical patent/MX9702336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a una composicion de vacuna adaptada para la administracion mucosal, y, en particular, para la administracion intranasal, esta composicion comprende uno o más antígenos de los virus de la influenza, tal como los antígenos del virus de la influenza de la hemaglutinina y la neuroaminidasa, y una cantidad efectiva de un adyuvante de una quitosán. Las composiciones se pueden usar para inmunizar a un huésped contra la infeccion de la influenza, este quitosán sirve para aumentar el estímulo de una respuesta protectora inmunologica mucosal de la IgA y una respuesta protectora inmunologica sistémica de IgG.
MX9702336A 1994-10-04 1995-09-21 Composiciones de vacuna. MX9702336A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9419979.1 1994-10-04
GB9419979A GB9419979D0 (en) 1994-10-04 1994-10-04 Vaccine compositions
PCT/GB1995/002231 WO1996010421A1 (en) 1994-10-04 1995-09-21 Vaccine compositions

Publications (2)

Publication Number Publication Date
MXPA97002336A MXPA97002336A (es) 1997-06-01
MX9702336A true MX9702336A (es) 1997-06-28

Family

ID=10762310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702336A MX9702336A (es) 1994-10-04 1995-09-21 Composiciones de vacuna.

Country Status (17)

Country Link
US (1) US6048536A (es)
EP (1) EP0784485B8 (es)
JP (1) JP4240237B2 (es)
KR (1) KR100373593B1 (es)
CN (1) CN1097467C (es)
AT (1) ATE229816T1 (es)
AU (1) AU710930B2 (es)
BR (1) BR9509190A (es)
CA (1) CA2201598C (es)
DE (1) DE69529224T2 (es)
DK (1) DK0784485T3 (es)
ES (1) ES2192582T3 (es)
GB (1) GB9419979D0 (es)
MX (1) MX9702336A (es)
NZ (1) NZ292953A (es)
TW (1) TW426521B (es)
WO (1) WO1996010421A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT700445E (pt) 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
AU754675B2 (en) * 1995-11-01 2002-11-21 Archimedes Development Limited Influenza vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
AU736318B2 (en) * 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
CA2255867C (en) * 1997-03-25 2008-02-05 Zonagen, Inc. Chitosan induced immunopotentiation
AU771525B2 (en) * 1997-03-25 2004-03-25 Zonagen, Inc. Chitosan induced immunopotentiation
ATE327259T1 (de) 1997-08-05 2006-06-15 Stressgen Biotechnologies Corp Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU762078B2 (en) * 1999-03-24 2003-06-19 Secretary Of State For Defence, The Vaccine composition
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
JP2003519668A (ja) 2000-01-14 2003-06-24 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
CA2487712A1 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
DE602004020189D1 (de) * 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
CN1301131C (zh) * 2003-04-11 2007-02-21 上海欣安基因免疫与疫苗研究开发有限公司 一种病毒性心肌炎基因疫苗及其制备方法和应用
EP1620732A2 (en) * 2003-04-30 2006-02-01 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
KR20070108371A (ko) * 2005-01-05 2007-11-09 필라델피아 헬스 앤드 에듀케이션 코퍼레이션 전달 비히클, 생물활성 물질 및 바이러스 백신
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
CA2552596A1 (en) * 2005-08-09 2007-02-09 Solvay Pharmaceuticals B.V. Methods and systems for determining mid-value titers
CN101450208B (zh) * 2008-12-31 2011-08-31 中国人民解放军军事医学科学院微生物流行病研究所 喷鼻免疫流感多价疫苗的制备及其方法
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
JP6534146B2 (ja) * 2015-06-10 2019-06-26 国立大学法人 東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5169840A (en) * 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
JP3109886B2 (ja) * 1991-12-13 2000-11-20 デンカ生研株式会社 経鼻接種用ワクチン
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
JPH06166635A (ja) * 1992-06-18 1994-06-14 San Five Kk 免疫アジュバント
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions

Also Published As

Publication number Publication date
JP4240237B2 (ja) 2009-03-18
DE69529224T2 (de) 2003-07-24
EP0784485A1 (en) 1997-07-23
ES2192582T3 (es) 2003-10-16
AU710930B2 (en) 1999-09-30
US6048536A (en) 2000-04-11
DE69529224D1 (de) 2003-01-30
BR9509190A (pt) 1997-10-21
WO1996010421A1 (en) 1996-04-11
KR100373593B1 (ko) 2003-05-09
GB9419979D0 (en) 1994-11-16
CN1159761A (zh) 1997-09-17
KR970706018A (ko) 1997-11-03
CN1097467C (zh) 2003-01-01
EP0784485B8 (en) 2003-05-02
CA2201598A1 (en) 1996-04-11
DK0784485T3 (da) 2003-04-07
EP0784485B1 (en) 2002-12-18
JPH10506405A (ja) 1998-06-23
CA2201598C (en) 2006-12-12
TW426521B (en) 2001-03-21
NZ292953A (en) 2001-03-30
AU3526995A (en) 1996-04-26
ATE229816T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
MX9702336A (es) Composiciones de vacuna.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
CA2311492A1 (en) Vaccines with an ltb adjuvant
WO2000047222A3 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
MX9803290A (es) Composiciones de la vacuna influenza.
GB9923176D0 (en) Novel composition
NO930938L (no) Forbedrede vaksiner
DK0764029T4 (da) Proteinadjuvanser
DK1053017T3 (da) Vacciner omfattende interleukin-12 og herpes simplex virusantigen
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
WO1999040937A3 (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens